Also known as 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol, 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)-2-propanol, 1-[2-(3,4-dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol, 1-(3,4-dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol, (+-)-bevantolol
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
via PubMed
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
==References==
via Wikidata sitelinks · CC0
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).